Mologen AG has advanced its study program according to plan in the first half of 2019 and successfully implemented capital measures to secure funding for the Company. Following a diligent approach to processing the study data for the initial evaluation of the Phase III IMPALA pivotal study with lefitolimod in the indication of metastatic colorectal cancer, the read-out of the top-line data was announced at the beginning of August. The primary study goal - a significant prolongation of overall survival of the patients - was not achieved. The beneficial safety profile and good tolerability of lefitolimod were again confirmed. Based on these results, MOLOGEN's future strategy will focus on developing combination therapies. In the indication of HIV/AIDS the Phase IIa TITAN combination study, for which Gilead is providing the funding, is about to start enrolling patients. In the indication of oncology, the combination study with the checkpoint inhibitor ipilimumab (Yervoy(R)) is continuing after the dosing escalation phase was successfully concluded. Furthermore, great progress has been made in plans for a clinical combination study with another checkpoint inhibitor. This would be conducted in collaboration with the strategic partner Oncologie Inc., which is based in Boston, USA. Forthcoming milestones include: the start of the TITAN study in HIV, the start of the clinical development of EnanDIM(R) and additional combination studies in cancer, including one with strategic partner Oncologie Inc., which are in an advanced planning stage.

The company announced earnings guidance for the full year 2019. The company announced that the statements made in the Forecast Report section of Management Report for fiscal year 2018 on the objectives in the areas of research and development, co-operations and partnerships, earnings and liquidity development as well as personnel remain valid.